PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease-Reference-Cited by-同舟云学术

PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease

Published:2021-05-14 Issue:12 Volume:62 Page:1747-1750
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Barbato Francesco,Fendler Wolfgang P.,Rauscher Isabel,Herrmann Ken,Wetter Axel,Ferdinandus Justin,Seifert Robert,Nader Michael,Rahbar Kambiz,Hadaschik Boris,Eiber Matthias,Gafita Andrei,Weber Manuel

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference11 articles.

1. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

2. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

3. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial;Fendler;JAMA Oncol.,2019

4. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer

5. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study;The Lancet Oncology;2024-09

2. Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group;Current Oncology;2024-06-03

3. Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy;BMC Cancer;2024-05-25

4. Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer;The Prostate;2024-05-15

5. Comparison of quantitative whole body PET parameters on [68Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer;Cancer Imaging;2024-05-06